AMERICAN JOINT COMMITTEE ON CANCER

美国联合委员会正在进行一项临床研究项目 制定所有解剖部位癌症的分期分类。 期间 去年，经过对 AJC 未来活动的深入思考， 制定了以下计划： 1) 进一步完成分类 需要开展的工作：骨骼、中枢神经系统、黑色素瘤和泌尿道恶性肿瘤； (2) 鼓励在最终结果报告中使用分类进行分期， 向期刊、图书馆、癌症登记处和医学会报告； 3） 与正在进行癌症分期的国家级团体合作，即 SEER、CCPDS、CICA、ACCC、ACOS 和其他中央和医院登记处， 开发通用计算机代码； （四）进一步细化、宣传、分发和 鼓励使用特定地点癌症数据收集表格； 5) 测试 分类的有效性，以及来自 SEER 和其他团体的数据； 6) 到 评估生物标志物和其他重要因素 特定癌症及其预后的分类，并确定其 相对重要性； 7）评估相对重要性和成本 治疗前临床中使用的各种测试和程序的有效性 分期和治疗后随访评估，以努力阻止 过度使用昂贵的检测，这些检测很少呈阳性，而且几乎没有增加 管理。

The American Joint Committee has been engaged in a clinical research project to develop staging classifications for cancer of all anatomic sites. During the past year following considerable thought as to the future activities of the AJC, the following plan has resulted: 1) To complete classifications where further work is needed: bone, central nervous system, melanoma, and GU malignancies; (2) To encourage the use of classification for staging in end results reporting, reporting to journals, libraries, cancer registries, and medical societies; 3) To work with groups on a national level who are doing cancer staging, i.e., SEER, CCPDS, CICA, ACCC, ACOS, and other central and hospital registries, to develop a common computer code; (4) To further refine, publicize, distribute and encourage use of specific site cancer data collection forms; 5) To test the validity of the classifications, with data from SEER and other groups; 6) To evaluate biological markers and other factors which are important in classification of specific cancers and their prognoses, and to determine their relative importance; 7) To evaluate the relative importance and cost effectiveness of various tests and procedures utilized in pretreatment clinical staging and in posttreatment follow-up evaluations, in an effort to discourage over-utilization of expensive tests which are rarely positive and add little to management.